Eli Lilly vs Novo Nordisk: One Winner in The Weight-Loss Drug Gold Rush

Eli Lilly (LLY) and Novo Nordisk (NVO) each reported Q2 2026 results in early August, but the article provides no specific figures or guidance changes. The “jarring” split-screen implies divergence in performance or market reaction, yet without reported magnitudes it is not possible to quantify impact. Overall news flow appears largely descriptive rather than price-moving based on the information given.